Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
DGKα Biochemical Activity Assay from US Patent US11926628: "Diacylglyercol kinase modulating compounds"
Assay data:155 Active, 154 Activity ≤ 1 µM, 155 Tested
SummaryRelated BioAssays by Target
PI3K-delta Scintillation Proximity Assay from US Patent US11926616: "Aminopyrazine diol compounds as PI3K-γ inhibitors"
Assay data:46 Active, 43 Activity ≤ 1 µM, 46 Tested
PI3K-gamma Scintillation Proximity Assay from US Patent US11926616: "Aminopyrazine diol compounds as PI3K-γ inhibitors"
Assay data:46 Active, 46 Activity ≤ 1 µM, 46 Tested
Biochemical Assay from US Patent US11926614: "1,2,4-triazole derivatives as tankyrase inhibitors"
Assay data:161 Active, 2 Activity ≤ 1 nM, 160 Activity ≤ 1 µM, 161 Tested
Measurement of A2A or A2B Binding Affinity Using Radioligand Binding from US Patent US20240076297: "ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY"
Assay data:28 Active, 3 Activity ≤ 1 nM, 28 Activity ≤ 1 µM, 28 Tested
Measurement of A2A or A2B Binding Affinity Using SPA from US Patent US20240076297: "ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY"
Assay data:18 Active, 15 Activity ≤ 1 µM, 18 Tested
Determination of the Inhibitory Activity of the Compounds on Human P2X3 and P2X2/3 Receptors from US Patent US11919918: "P2X3 andor P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof"
Assay data:106 Active, 101 Activity ≤ 1 µM, 106 Tested
CDK2/Cyclin E1 HTRF Enzyme Activity Assay from US Patent US11919904: "Sulfonylamide compounds as CDK2 inhibitors"
Assay data:14 Active, 14 Activity ≤ 1 µM, 14 Tested
Determination of Binding Constants to Menin-MLL from US Patent US11919901: "Inhibitors of the menin-MLL interaction"
Assay data:253 Active, 249 Activity ≤ 1 nM, 253 Activity ≤ 1 µM, 253 Tested
Menin-MLL Competition Assay from US Patent US11919901: "Inhibitors of the menin-MLL interaction"
Assay data:51 Active, 51 Activity ≤ 1 µM, 51 Tested
In Vitro Test of Activities of Jak1, Jak2, Jak3, Tyk2 Kinases from US Patent US11919896: "[1,2,4]triazolo[1,5-a]pyridine compound as JAK inhibitor and use thereof"
Assay data:14 Active, 1 Activity ≤ 1 µM, 34 Tested
Assay data:34 Active, 22 Activity ≤ 1 µM, 34 Tested
Assay data:34 Active, 34 Activity ≤ 1 µM, 34 Tested
Assay data:33 Active, 28 Activity ≤ 1 µM, 34 Tested
E-VIPR Assay Detecting and Measuring Nav Inhibition Properties from US Patent US11919887: "Substituted tetrahydrofurans as modulators of sodium channels"
Assay data:54 Active, 107 Activity ≤ 1 µM, 107 Tested
AlphaScreen Assay from US Patent US11919855: "Substituted pyrrolidones and piperidones as small molecule inhibitors of EZH2 and EED protein binding"
Assay data:30 Active, 9 Activity ≤ 1 µM, 103 Tested
In Vitro JAK Kinase Assay from US Patent US11918581: "Combination therapy comprising JAK pathway inhibitor and rock inhibitor"
Assay data:26 Active, 26 Activity ≤ 1 µM, 26 Tested
NAMPT Enzyme Activating Effect (In Vitro Cell-Free Enzyme Assay from US Patent US11918568: "Fused ring compound having urea structure"
Assay data:55 Active, 55 Activity ≤ 1 µM, 55 Tested
ASGPR Measured Using Surface Plasmon Resonance (SPR) from US Patent US20240072809: "ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS"
Assay data:186 Tested
homogeneous time-resolved fluorescence (HTRF) binding assay from US Patent US20240067660: "MACROCYCLIC SPIROCYCLE DERIVATIVES AS MCL-1 INHIBITORS"
Assay data:36 Active, 25 Activity ≤ 1 nM, 36 Activity ≤ 1 µM, 36 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on